← 返回

基于固有免疫的聚类揭示了骨髓增生异常肿瘤中基于疾病严重程度的差异性失调

英文原题:Clustering Based on Innate Immunity Reveals Differential Dysregulation Based on Disease Severity in Myelodysplastic Neoplasms.

查看英文原题

Clustering Based on Innate Immunity Reveals Differential Dysregulation Based on Disease Severity in Myelodysplastic Neoplasms.

PubMed 2025/05/01(内容时间) Hematol Oncol Q1 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

骨髓增生异常肿瘤(MDS)是一类克隆性血液系统疾病,以无效造血和进展为急性髓系白血病(AML)的可变风险为特征。尽管先天免疫在MDS发病机制中的作用日益受到认可,但其确切机制仍不清楚。

在本研究中,我们分析了183例MDS患者的骨髓CD34+表达数据,以探讨Toll样受体(TLR)通路对疾病进展的影响。使用六个关键先天免疫基因(IRAK1、IRAK2、IRAK4、MYD88、TRAF6和NFKB1)定义了两种不同的免疫聚类:高活性免疫聚类(HIC)和中等免疫聚类(MIC)。HIC富集了155条免疫相关通路,并显示活化NK 细胞和M1巨噬细胞浸润较高,而MIC则表现出初始B细胞和肥大细胞浸润增加。差异表达分析鉴定出35个可区分这些聚类的基因。在82例患者的独立队列中进行验证显示,这些基因表达降低与晚期疾病标志物相关,包括较低的血红蛋白水平、较低的中性粒细胞计数、细胞遗传学改变以及较高的骨髓原始细胞百分比。这些发现强调了免疫失调在MDS进展中的关键作用,并突出了先天免疫通路中用于定制化干预的新治疗机会。

展开英文摘要原文

Myelodysplastic neoplasms (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis and a variable risk of progression to acute myeloid leukemia (AML). Despite growing recognition of the role of innate immunity in MDS pathogenesis, the precise mechanisms remain unclear. In this study, we analyzed bone marrow CD34+ expression data from 183 MDS patients to investigate the impact of the Toll-like receptor (TLR) pathway on disease progression. Six key innate immunity genes (IRAK1, IRAK2, IRAK4, MYD88, TRAF6, and NFKB1) were used to define two distinct immune clusters: a hyperactive immune cluster (HIC) and a moderate immune cluster (MIC).

The HIC was enriched in 155 immune-related pathways and showed higher infiltration of activated natural killer cells and M1 macrophages, while the MIC exhibited increased infiltration of naïve B cells and mast cells. Differential expression analysis identified 35 genes that distinguished the clusters.

Validation in an independent cohort of 82 patients revealed that reduced expression of these genes correlated with markers of advanced disease, including lower hemoglobin levels, lower neutrophil counts, altered cytogenetics, and higher bone marrow blast percentages.

These findings underscore the critical role of immune dysregulation in MDS progression and highlight novel therapeutic opportunities within the innate immunity pathway for tailored interventions.

论文信息

作者
Passos PRC、Vieira AA、de Melo RPM、Pinheiro Filho RF、Sampaio LG、Santos HVGD、Sampaio LR、Goes JVC
单位
Laboratory of Cancer Cytogenetics, Federal University of Ceará, Fortaleza, Brazil.Brazil
期刊
Hematological oncology2025 May
原文标识
PubMed 40397075 · DOI 10.1002/hon.70104